At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 60 enrolled
Drug / intervention
E/C/F/TAFdrug
Likely dose
E/C/F/TAF 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents
In Brief
A Phase 3 clinical trial evaluating E/C/F/TAF for HIV. Completed, enrolled 60 participants across 7 sites in 2 countries.
Detailed Summary
The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected virologically suppressed adolescents 12 to \< 18 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesSouth Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartDec 2014
Primary CompletionNov 2016
Study CompletionOct 2017
TodayJul 2026
First PostedOct 28, 2014
Enrollment StartDec 3, 2014
Primary CompletionNov 10, 2016
Study CompletionOct 23, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.7 years ago
Interventions
E/C/F/TAFdrug
150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food